These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: IL-2 -330T/G polymorphism and cancer risk: a meta-analysis.
    Author: Zhao H, Wang R.
    Journal: Onco Targets Ther; 2015; 8():1753-60. PubMed ID: 26229483.
    Abstract:
    PURPOSE: Some studies have investigated the association of IL-2 -330T/G (rs2069762) polymorphism with cancer risk, but the previous results were conflicting and had relatively low statistical power. Thus, we performed a meta-analysis to derive a more precise estimation of the association between IL-2 -330T/G polymorphism and cancer risk. METHODS: A literature search was performed systematically using electronic databases. The odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. RESULTS: A total of ten studies including 3,060 cases and 3,435 controls were involved in this meta-analysis. The results indicated that IL-2 -330T/G polymorphism was significantly associated with cancer risk ([OR =2.03, 95% CI =1.40-2.95] for GG vs TT; [OR =1.37, 95% CI =1.11-1.69] for GT vs TT; [OR =1.46, 95% CI =1.18-1.81] for [GG + GT] vs TT; [OR =1.66, 95% CI =1.24-2.23] for GG vs [GT + TT]; and [OR =1.35, 95% CI =1.16-1.57] for G vs T). In the subgroup analysis according to cancer type, significant association was found in lymphoma ([OR =1.46, 95% CI =1.11-1.91] for GT vs TT; [OR =1.58, 95% CI =1.22-2.05] for [GG + GT] vs TT; [OR =1.84, 95% CI =1.22-2.77] for GG vs [GT + TT]) and other cancers, but not in gastric cancer. In the subgroup analysis by ethnicity, the significant risk was found among Asians, but not among Europeans. CONCLUSION: This meta-analysis suggests that IL-2 -330T/G polymorphism has an increased risk of cancer in Asians. However, further detailed studies are still required to confirm our findings.
    [Abstract] [Full Text] [Related] [New Search]